Sarepta Therapeutics (SRPT) Named Top 2nd-Half SMID Biotech Pick at BofA/Merrill Lynch
Tweet Send to a Friend
BofA/Merrill Lynch analyst Tazeen Ahmad named Sarepta Therapeutics (NASDAQ: SRPT) its SMID Biotech 2nd-Half 2019 top pick. The analyst reiterated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
